Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Low-cost blood pressure lowering drugs, statins and aspirin widely in the form of a single pill, also known as the polypill. McMaster University

News | Pharmaceuticals

The Polypill Could Avoid Millions of Premature Deaths, Heart Attacks and Strokes Every Year, Say Leading Cardiology Experts

October 17, 2022 — Global Health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs ...

October 17, 2022

Study investigates metformin and other candidate drugs through a network medicine approach

News | Heart Failure

Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research

October 12, 2022 — Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible ...

October 12, 2022

Prespecified meta-analysis of DELIVER and EMPEROR-Preserved presented in a Hot Line Session at ESC Congress 2022

News | Pharmaceuticals

Meta-Analysis Strengthens Evidence for SGLT2 Inhibitors in Patients With Heart Failure

September 6, 2022 — An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empag ...

September 06, 2022

Stopping statin treatment early could substantially reduce lifetime protection against heart disease since a large share of the benefit occurs later in life

News | Pharmaceuticals

Study Highlights Lifelong Benefits of Statin Therapy

September 6, 2022 — Stopping statin treatment early could substantially reduce lifetime protection against heart disease ...

September 06, 2022

SECURE trial presented in a Hot Line Session today at ESC Congress 2022

News | ESC

Polypill Reduces Cardiovascular Events in Heart Attack Patients Compared to Usual Care

August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively prevents ...

August 30, 2022

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick look back in heart history at four individuals who earned their place in the National Inventors Hall of Fame

Feature | Cardiovascular Business | By Christine Book

At the Intersection of History and Heart Health: Inventors Hall of Fame Inductees

As the cardiology community commemorates the importance of heart health on World Heart Day, Sept. 29, here’s a quick ...

August 18, 2022

Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint

News | Pharmaceuticals

dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

July 25, 2022 DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine ...

July 25, 2022

Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022

News | Pharmaceuticals

Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

May 24, 2022

The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States.

News | Pharmaceuticals

Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

May 24, 2022

Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

News | Pharmaceuticals

Research Shows Potential to Reduce Major Cardiovascular (CV) Events

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

May 17, 2022

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

News | Pharmaceuticals

Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

May 13, 2022

$Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction$

News | Cardiovascular Clinical Studies

FARXIGA Met Primary Endpoint in DELIVER Phase III Trial

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

May 05, 2022

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo

News | Pharmaceuticals

FDA Approves Bristol Myers' Camzyos (mavacamten) Oral Heart Disease Drug

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

April 29, 2022

News | Heart Failure

Mavacamten Dramatically Cuts Need for Surgical Intervention for People with Obstructive Hypertrophic Cardiomyopathy

April 12, 2022 – A majority of patients with obstructive hypertrophic cardiomyopathy (HCM)—a condition that results in ...

April 12, 2022

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology’s 71st Annual Scientific Session.

News | Heart Failure

Patiromer Helps Patients Stay on Optimal Heart Failure Therapy

April 8, 2022 – Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had ...

April 08, 2022